Category: Latest News
-
Mill City shares jump following $450M private placement to build Sui crypto treasury
Mill City Ventures III, Ltd. (NASDAQ:MCVT) saw its stock climb 20% after announcing a $450 million private placement aimed at creating a treasury reserve centered on the Sui blockchain cryptocurrency. The Minnesota-based specialty finance firm intends to allocate roughly 98% of the net proceeds to purchasing SUI tokens, the native currency of the Sui blockchain,…
-
BeOne Medicines shares climb following positive EU backing for lung cancer therapy
BeOne Medicines AG (NASDAQ:ONC) saw its stock rise 2.5% in pre-market trading after the European Medicines Agency (EMA) issued a favorable opinion on its cancer drug TEVIMBRA for early-stage lung cancer. The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of TEVIMBRA (tislelizumab), combined with platinum-based chemotherapy, for adult patients with resectable…
-
Upexi shares climb following $500 million equity line agreement
Upexi Inc (NASDAQ:UPXI) saw its stock jump 5.1% in pre-market trading after revealing a new equity line deal with A.G.P./Alliance Global Partners (NYSE:GLP). This agreement allows Upexi to sell up to $500 million of its common shares at its own discretion. With no commitment fees involved, the pact offers Upexi greater flexibility to raise funds…
-
Sidus Space shares plunge following public offering pricing
Sidus Space Inc (NASDAQ:SIDU) saw its stock drop sharply by 46.5% in pre-market trading after the space and defense tech firm announced the pricing of a public offering that will notably dilute current shareholders. The company set the price for a best-efforts offering of 7,143,000 shares of Class A common stock at $1.05 each, targeting…
-
Maia Biotechnology shares jump after FDA awards Fast Track status
Maia Biotechnology Inc (AMEX:MAIA) saw its stock surge 11.2% in pre-market trading following the announcement that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to its cancer drug ateganosine. This designation, given for the treatment of non-small cell lung cancer (NSCLC), could speed up the drug’s regulatory review process. Ateganosine is currently…
-
Stereotaxis shares jump after FDA approves robotic mapping catheter
Shares of Stereotaxis (AMEX:STXS) climbed 12% following the U.S. Food and Drug Administration’s (FDA) 510(k) clearance of its MAGiC Sweep catheter, the first-ever robotically navigated high-density electrophysiology mapping catheter worldwide. The MAGiC Sweep catheter marks a major technological breakthrough in the diagnosis and treatment of complex arrhythmias. Featuring 20 electrodes, the device enables fast and…
-
Weekly Outlook: Dow, Nasdaq, and S&P 500 Eye Mag-7 Earnings as August 1 Tariff Deadline Nears
U.S. stock markets ended Friday on a high note, capping a strong week fueled by upbeat corporate earnings and encouraging trade news. The S&P 500 gained 0.40% to close at a new record high of 6,388.64, marking its 14th all-time peak this year. The Nasdaq Composite also reached fresh heights, adding 0.24% to finish at…
-
U.S. LNG Stocks Jump After EU Commits to Massive Fuel Purchases in Landmark Deal
Shares of major U.S. liquefied natural gas (LNG) developers surged on Monday morning following the announcement of a sweeping trade agreement in which the European Union agreed to buy $750 billion worth of LNG from the United States over the next three years. The framework deal, unveiled Sunday, commits the EU to annual purchases of…
-
Provident Financial Misses Q4 Estimates as Profit Drops on Higher Costs, Weaker Fee Income
Provident Financial Holdings, Inc. (NASDAQ:PROV) reported fourth-quarter earnings that missed analyst projections, as a rise in operating costs and a drop in non-interest income led to a 17% decline in net profit compared to the same period a year earlier. For the quarter ending June 30, 2025, the parent of Provident Savings Bank posted net…
-
Revvity Surpasses Q2 Forecasts with Solid Revenue Growth Across Divisions
Revvity, Inc. (NYSE:RVTY) reported stronger-than-expected results for the second quarter, with steady revenue gains across its Life Sciences and Diagnostics segments, despite a complex economic backdrop. The company delivered adjusted earnings per share of $1.18, beating Wall Street expectations of $1.14. Total revenue reached $720 million, exceeding the average analyst forecast of $710.39 million. Compared…